[go: up one dir, main page]

EA200801275A1 - Стабилизированные составы карбоната лантана - Google Patents

Стабилизированные составы карбоната лантана

Info

Publication number
EA200801275A1
EA200801275A1 EA200801275A EA200801275A EA200801275A1 EA 200801275 A1 EA200801275 A1 EA 200801275A1 EA 200801275 A EA200801275 A EA 200801275A EA 200801275 A EA200801275 A EA 200801275A EA 200801275 A1 EA200801275 A1 EA 200801275A1
Authority
EA
Eurasian Patent Office
Prior art keywords
stabilized
lantan
carbonate compositions
lanthanum carbonate
compositions
Prior art date
Application number
EA200801275A
Other languages
English (en)
Russian (ru)
Inventor
Джозефин Кристин Фердинандо
Питер Нейл Дэвис
Original Assignee
Шир Интернэшнл Лайсенсинг Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37434215&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200801275(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шир Интернэшнл Лайсенсинг Б.В. filed Critical Шир Интернэшнл Лайсенсинг Б.В.
Publication of EA200801275A1 publication Critical patent/EA200801275A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA200801275A 2005-11-09 2006-11-07 Стабилизированные составы карбоната лантана EA200801275A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/272,569 US7381428B2 (en) 2003-08-26 2005-11-09 Stabilized lanthanum carbonate compositions
PCT/IB2006/003141 WO2007054782A1 (en) 2005-11-09 2006-11-07 Stabilized lanthanum carbonate compositions

Publications (1)

Publication Number Publication Date
EA200801275A1 true EA200801275A1 (ru) 2008-10-30

Family

ID=37434215

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200801275A EA200801275A1 (ru) 2005-11-09 2006-11-07 Стабилизированные составы карбоната лантана

Country Status (16)

Country Link
US (2) US7381428B2 (xx)
EP (1) EP1785141A1 (xx)
JP (1) JP2009514940A (xx)
KR (1) KR20080071170A (xx)
CN (1) CN101378767A (xx)
AR (1) AR056609A1 (xx)
AU (1) AU2006313490A1 (xx)
BR (1) BRPI0619673A2 (xx)
CA (1) CA2626894A1 (xx)
EA (1) EA200801275A1 (xx)
IL (1) IL190858A0 (xx)
NO (1) NO20082538L (xx)
PE (1) PE20070821A1 (xx)
TW (1) TW200733968A (xx)
WO (1) WO2007054782A1 (xx)
ZA (1) ZA200804852B (xx)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9720061D0 (en) 1997-09-19 1997-11-19 Crosfield Joseph & Sons Metal compounds as phosphate binders
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
PT1660104E (pt) * 2003-08-26 2010-06-15 Shire Holdings Ag Formulação farmacêutica compreendendo compostos de lantânio
BRPI0513603A (pt) * 2004-07-27 2008-05-13 Shire Pharmaceuticals Inc uso de hidroxicarbonato de lantánio e composição farmacêutica
US20060134225A1 (en) * 2004-10-15 2006-06-22 Moerck Rudi E Phosphate binder with reduced pill burden
GB0502787D0 (en) * 2005-02-10 2005-03-16 Ineos Silicas Ltd Pharmaceuticlly active compounds, their manufacture, compositions containing them and their use
WO2007022445A2 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
MY157620A (en) 2006-01-31 2016-06-30 Cytochroma Dev Inc A granular material of a solid water-soluble mixed metal compound capable of binding phosphate
US20070259052A1 (en) * 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
GB0714670D0 (en) * 2007-07-27 2007-09-05 Ineos Healthcare Ltd Use
GB0720220D0 (en) * 2007-10-16 2007-11-28 Ineos Healthcare Ltd Compound
US8974824B2 (en) * 2008-03-26 2015-03-10 Mylan Laboratories Ltd. Lanthanum composition
WO2010022380A2 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Linear polyol stabilized polyfluoroacrylate compositions
KR101825113B1 (ko) 2008-08-22 2018-02-02 리립사, 인크. 가교결합된 양이온교환 폴리머, 조성물 및 고칼륨혈증 치료 용도
EP2389070B1 (en) * 2009-01-21 2013-07-31 Mylan Inc. Disintegrable formulations of lanthanum carbonate
GB0913525D0 (en) 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
WO2011051968A2 (en) * 2009-10-26 2011-05-05 Alkem Laboratories Ltd. Pharmaceutical compositions of lanthanum carbonate and process for the preparation thereof
GB201001779D0 (en) 2010-02-04 2010-03-24 Ineos Healthcare Ltd Composition
CA2798081C (en) 2010-05-12 2024-02-13 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
EP2441436A1 (de) * 2010-10-13 2012-04-18 Fresenius Medical Care Deutschland GmbH Phosphatbinderformulierung zur einfachen Einnahme
US8697132B2 (en) 2010-12-01 2014-04-15 Shire Llc Capsule and powder formulations containing lanthanum compounds
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
WO2012098562A2 (en) * 2011-01-19 2012-07-26 Panacea Biotec Limited Liquid oral compositions of lanthanum salts
CN103145170A (zh) * 2013-03-27 2013-06-12 吉首大学 超临界二氧化碳与氧化镧反应制备碳酸镧的方法
JP2016147827A (ja) * 2015-02-12 2016-08-18 株式会社三和化学研究所 炭酸ランタン水和物を含有する医薬製剤
US10058569B2 (en) 2015-06-24 2018-08-28 Lupin Limited Lanthanum carbonate compositions
JP6623753B2 (ja) * 2015-12-28 2019-12-25 ニプロ株式会社 炭酸ランタンを含む口腔内崩壊錠
JP2020033303A (ja) * 2018-08-30 2020-03-05 コーアイセイ株式会社 炭酸ランタンを含有する安定な口腔内速崩壊性錠剤
CN108969497A (zh) * 2018-10-12 2018-12-11 沈阳华泰药物研究有限公司 一种碳酸镧片剂组合物及其制备方法
CA3125292A1 (en) * 2019-01-04 2020-07-09 Kaydence Pharma As Combination therapy of phosphate binders and vitamin k
WO2021101461A1 (en) 2019-11-21 2021-05-27 Santa Farma İlaç Sanayi̇ A.Ş. Oral solid pharmaceutical compositions comprising lanthanum carbonate octahydrate
CN113244179B (zh) * 2021-05-21 2023-01-13 浙江仟源海力生制药有限公司 一种稳定性好的碳酸镧片剂及其制备方法和其应用
CN115813867B (zh) * 2022-12-01 2024-05-24 山东齐都药业有限公司 碳酸镧冻干片及其制备方法
CN119455019B (zh) * 2024-11-27 2025-10-28 北京华睿鼎信科技有限公司 碳酸镧药用组合物及其应用与治疗高磷血症的药物

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54155675A (en) * 1978-05-30 1979-12-07 Matsushita Electronics Corp Small-sized fluorescent lamp
JPH06705B2 (ja) 1985-12-19 1994-01-05 旭化成工業株式会社 リン酸イオンの固定化剤
US4822594A (en) 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
JPS6485088A (en) 1987-06-19 1989-03-30 Takeda Chemical Industries Ltd Production of 2-keto-l-gulonic acid
US4877735A (en) 1987-06-19 1989-10-31 Takeda Chemical Industries, Ltd. Process for producing 2-keto-L-gulonic acid
DE3724188C2 (de) 1987-07-17 1995-05-18 Heinz Dr Gries Metallhaltige Oligosaccharid-Polysulfate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Mittel
EP0620728B1 (en) * 1992-01-13 1997-01-08 Pfizer Inc. Preparation of tablets of increased strength
ATE208611T1 (de) * 1994-05-20 2001-11-15 Janssen Pharmaceutica Nv Flubendazole-kautabletten für haustiere
JP3591886B2 (ja) 1994-09-05 2004-11-24 シーシーアイ株式会社 希土類元素集積微生物
GB9506126D0 (en) 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6074672A (en) 1996-06-28 2000-06-13 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Powdered cosmetic compositions containing silicone elastomers
US20010014352A1 (en) * 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
JP2000173537A (ja) * 1998-09-29 2000-06-23 Toshiba Lighting & Technology Corp 低圧水銀蒸気放電灯および照明装置
GB0008392D0 (en) 2000-04-05 2000-05-24 Unilever Plc Process for the production of a deodorant or antiperspirant product
GB0015745D0 (en) 2000-06-27 2000-08-16 Shire Holdings Ag Treatment of bone diseases
US20020057059A1 (en) * 2000-07-28 2002-05-16 Kazuhisa Ogishi Fluorescent lamp, self-ballasted fluorescent lamp and lighting apparatus
JP2002047210A (ja) 2000-08-04 2002-02-12 Nihon Medi Physics Co Ltd 尿路結石防止用組成物
JP4612183B2 (ja) 2000-12-27 2011-01-12 株式会社ヤクルト本社 皮膚外用組成物及びその製造方法
EP1344528B1 (en) 2000-12-19 2008-10-08 Kabushiki Kaisha Yakult Honsha External skin preparations and process for producing the same
JP4612180B2 (ja) 2000-12-19 2011-01-12 株式会社ヤクルト本社 皮膚外用剤
US20020122823A1 (en) * 2000-12-29 2002-09-05 Bunick Frank J. Soft tablet containing dextrose monohydrate
EP1389102B1 (en) 2001-04-23 2011-03-02 Shire International Licensing B.V. Use of lanthanum carbonate for the prevention of kidney stone disease
GB0201607D0 (en) 2002-01-24 2002-03-13 Gamlen Michael J D Formulation for the administration of medicinal substances
ES2322896T3 (es) * 2002-04-29 2009-07-01 Supernus Pharmaceuticals, Inc. Formulaciones farmaceuticas con biodisponibilidad mejorada.
AU2003229437A1 (en) 2002-05-08 2003-11-11 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20040161474A1 (en) 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
AU2003282867A1 (en) 2002-10-22 2004-05-13 Genzyme Corporation Amine polymers for promoting bone formation
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
PT1660104E (pt) 2003-08-26 2010-06-15 Shire Holdings Ag Formulação farmacêutica compreendendo compostos de lantânio
US7459502B2 (en) 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7545784B2 (en) * 2004-02-11 2009-06-09 Yahoo! Inc. System and method for wireless communication between previously known and unknown users
US7854924B2 (en) 2004-03-30 2010-12-21 Relypsa, Inc. Methods and compositions for treatment of ion imbalances
US8192758B2 (en) 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
US8282960B2 (en) 2004-03-30 2012-10-09 Relypsa, Inc. Ion binding compositions
GB2430367B (en) 2004-03-30 2009-08-05 Ilypsa Inc Ion binding polymers and uses thereof

Also Published As

Publication number Publication date
US20080187602A1 (en) 2008-08-07
CN101378767A (zh) 2009-03-04
US20060121127A1 (en) 2006-06-08
JP2009514940A (ja) 2009-04-09
KR20080071170A (ko) 2008-08-01
EP1785141A1 (en) 2007-05-16
NO20082538L (no) 2008-06-06
PE20070821A1 (es) 2007-09-22
CA2626894A1 (en) 2007-05-18
AU2006313490A1 (en) 2007-05-18
AR056609A1 (es) 2007-10-17
TW200733968A (en) 2007-09-16
IL190858A0 (en) 2008-11-03
ZA200804852B (en) 2009-06-24
BRPI0619673A2 (pt) 2011-10-11
WO2007054782A1 (en) 2007-05-18
US7381428B2 (en) 2008-06-03

Similar Documents

Publication Publication Date Title
EA200801275A1 (ru) Стабилизированные составы карбоната лантана
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
SE0301700D0 (sv) Novel compounds
EP2269631A3 (en) Pharmaceutical compositions comprising botulinum neurotoxin for use in medicine and cosmetics
IL178128A0 (en) Salts of 3-0-(3',3'-dimethyl-succinyl) betulinic acid and pharmaceutical compositions containing the same
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
NO20075111L (no) Farmasoytisk sammensetning
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
NO20064584L (no) Tetrahydropyridoindolderivater
CL2007001917A1 (es) Compuestos derivados de azaindol espirociclicos; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del dolor, condiciones de panico, depresion, mal de alzheimer, migrana, entre otras.
WO2007127333A3 (en) Compositions for the treatment and prevention of eyelid swelling
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
MX2010005012A (es) Composiciones para el tratamieno y prevencion de inflamacion de los parpados que comprenden un ingrediente osmoticamente activo y un vasocosntrictor.
IL190915A0 (en) Dry formulations of aripiprazole
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
ZA200801575B (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
EP2015740A4 (en) NEW LOW-DOSED PHARMACEUTICAL COMPOSITIONS WITH NIMESULID, PREPARATION AND USE
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
UA91848C2 (ru) Применение соединений диосметина в лечении и предотвращении тромботическим патологиям
MX2010004899A (es) Conjugados de neurturina novedosos para uso farmaceutico.
PT1883452E (pt) Composição farmacêutica contendo um agente antiparasítico e um agente ativo escolhido entre timol, eugenol ou carvacrol
TW200507838A (en) Active substance combination comprising a 2,5-dihydroxybenzenesulfonic compound and a potassium ion channel modulator
GB0524814D0 (en) Compounds